After Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge

• Imara Inc (NASDAQ: IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.

• In addition to $250,000 previously paid by Cardurion upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront payment of $34.75 million and $60 million as milestone payments.

• In case of termination, the company would be obligated to pay a fee of $1.5 million Cardurion.

• In April, Imara posted interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.

• No meaningful benefit was observed in transfusion burden in either tovinontrine group compared to the placebo in the beta-thalassemia study.

• Imara announced discontinuing the Ardent and Forte trials and further developing tovinontrine in sickle cell disease and beta-thalassemia.

• Price Action: IMRA shares are up 37.60% at $1.61 during the premarket session on the last check Wednesday.

See more from Benzinga

• Top Financial Stories Wednesday, September 07: Musk Cited Putin Worries To Delay Twitter Deal, Apple To Defend Move Of Selling iPhones Without Charger, Deutsche Bank CEO Signals Recession Risks And More..

• Baker Hughes To Simplify Organizational Structure With Two Business Units

• Tesla Motors (TSLA) – If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much Y

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.